recombinant Coxsackie virus B3 injection (Wuhan Boweide Biotechnology)

N/A

Report date: 2025/03/20 09:43:18

Base Information

Drug Namerecombinant Coxsackie virus B3 injection (Wuhan Boweide Biotechnology)
Drug Alias Nameoncolytic coxsackievirus therapy (Wuhan Boweid Biotechnology)WeiBoEn
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuhan Boweid Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Boweid Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A